EXEL Logo

Exelixis, Inc. (EXEL) 

NASDAQ
Market Cap
$10.41B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
43 of 971
Rank in Industry
35 of 557

Largest Insider Buys in Sector

EXEL Stock Price History Chart

EXEL Stock Performance

About Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Insider Activity of Exelixis, Inc.

Over the last 12 months, insiders at Exelixis, Inc. have bought $12.67M and sold $25.28M worth of Exelixis, Inc. stock.

On average, over the past 5 years, insiders at Exelixis, Inc. have bought $7.63M and sold $25.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: JOHNSON DAVID EDWARD (director) — $38M.

The last purchase of 225,000 shares for transaction amount of $4.67M was made by JOHNSON DAVID EDWARD (director) on 2024‑05‑30.

List of Insider Buy and Sell Transactions, Exelixis, Inc.

2024-11-22SaleEVP, Commercial
10,000
0.0035%
$35.27$352,700+2.26%
2024-11-18SaleEVP, Commercial
41,588
0.0145%
$34.36$1.43M+1.19%
2024-11-05SaleCSO/EVP Disc & Trans Research
96,986
0.0346%
$35.00$3.39M+0.41%
2024-11-01SaleEVP & General Counsel
50,000
0.0175%
$34.13$1.71M+4.92%
2024-11-01Saledirector
30,000
0.0105%
$34.00$1.02M+4.92%
2024-10-30SaleCSO/EVP Disc & Trans Research
1,162
0.0004%
$31.40$36,487+9.77%
2024-10-28SaleEVP & General Counsel
25,000
0.0086%
$28.39$709,750+6.46%
2024-09-23SaleEVP & General Counsel
25,000
0.0088%
$26.38$659,500+17.20%
2024-08-26SaleEVP, General Counsel & Sec
20,000
0.007%
$25.79$515,800+4.26%
2024-08-14Saledirector
8,250
0.0028%
$26.56$219,1200.00%
2024-08-12SaleCSO/EVP Disc & Trans Research
20,883
0.0073%
$27.06$565,094-1.43%
2024-08-09SaleEVP and CFO
125,000
0.0442%
$27.19$3.4M-1.41%
2024-08-08Saledirector
33,725
0.0115%
$26.89$906,865-2.01%
2024-08-07SaleEVP, General Counsel & Sec
80,000
0.0269%
$25.97$2.08M+0.53%
2024-08-07SaleCSO/EVP Disc & Trans Research
95,000
0.0307%
$25.00$2.38M+0.53%
2024-08-07SaleEVP, Commercial
14,000
0.0046%
$25.50$357,000+0.53%
2024-06-04Saledirector
8,287
0.0029%
$22.00$182,314+20.81%
2024-05-30Purchasedirector
225,000
0.0772%
$20.76$4.67M+25.75%
2024-05-28Purchasedirector
200,000
0.0686%
$20.32$4.06M+28.08%
2024-05-21Saledirector
11,686
0.004%
$20.96$244,939+23.42%

Insider Historical Profitability

73.97%
JOHNSON DAVID EDWARDdirector
1525730
0.5343%
$36.4641
PAPADOPOULOS STELIOSdirector
1260578
0.4414%
$36.46211+117.05%
Senner Christopher J.EVP and CFO
721680
0.2527%
$36.46012
Hessekiel JeffreyEVP & General Counsel
530325
0.1857%
$36.46036
Aftab DanaCSO/EVP Disc & Trans Research
498945
0.1747%
$36.4606
WYSZOMIERSKI JACK Ldirector
349499
0.1224%
$36.46010
Haley Patrick J.EVP, Commercial
278665
0.0976%
$36.46053
POSTE GEORGEdirector
169020
0.0592%
$36.46012
Freire Maria Cdirector
91007
0.0319%
$36.4602
Garber Alan Mdirector
35703
0.0125%
$36.46013
Smith Juliedirector
5445
0.0019%
$36.4601
DUYK GEOFFREY MPres R&D & CSO
941355
0.3296%
$36.46019
SCANGOS GEORGE Adirector
714717
0.2503%
$36.461243+51.69%
Schwab GiselaPres, Prod Dev & Med Aff & CMO
614078
0.215%
$36.46137+9.5%
FORMELA JEAN FRANCOISdirector
584519
0.2047%
$36.46026
WILLSEY LANCE
424415
0.1486%
$36.461212+142.31%
Lamb PeterEVP, Scientific Strategy & CSO
410958
0.1439%
$36.46027
SATO GLEN YCFO Sec and General Counsel
258266
0.0904%
$36.4601
COHEN CHARLESdirector
181375
0.0635%
$36.46011
STALDER PETERdirector
96458
0.0338%
$36.4602
MORRISSEY MICHAELPresident and CEO
85985
0.0301%
$36.46160+201.22%
MARCHESI VINCENT Tdirector
66115
0.0232%
$36.461313+2.14%
KARBE FRANKEVP & CFO
60110
0.021%
$36.4630+92.47%
FELDBAUM CARL Bdirector
18701
0.0065%
$36.46012
FISHERMAN JASON S
7881
0.0028%
$36.4602
BALL KRISTINE MController & Interim CFO
4913
0.0017%
$36.4602
Heller Frances KEVP, Business Development
1500
0.0005%
$36.4602
SIMONTON PAMELA ASVP, Patents & Licensing
0
0%
$36.4608
RIVERA LUPE MEVP, Operations
0
0%
$36.4606

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$827.76M11.9834.88M-3.14%-$26.86M0.02
The Vanguard Group$731.35M10.5830.82M-2.69%-$20.2M0.01
Farallon Capital$633.08M9.1626.68M+0.17%+$1.04M4.45
Renaissance Technologies$358.36M5.1815.1M-3.29%-$12.2M0.57
State Street$310.42M4.4913.08M+0.37%+$1.15M0.01
JPMorgan Chase$126.34M1.835.32M-31.23%-$57.37M0.01
Geode Capital Management$124.41M1.85.24M+1.87%+$2.29M0.01
Dimensional Fund Advisors$113.6M1.644.79M+4.97%+$5.38M0.03
Morgan Stanley$111.38M1.614.69M-1.69%-$1.92M0.01
Nuveen$95.07M1.384.01M+15.16%+$12.51M0.03
Stephens Investment Management Group LLC$92.87M1.343.91M-4.7%-$4.58M1.24
Charles Schwab$79.94M1.163.37M+0.12%+$98,360.850.02
T. Rowe Price$79.22M1.153.34M-8.53%-$7.39M0.01
First Trust$70.56M1.022.97M-5.68%-$4.25M0.07
AQR Capital$69.09M12.91M+33.63%+$17.39M0.11
BNY Mellon$65.86M0.952.78M-7.39%-$5.25M0.01
LSV Asset Management$65.84M0.952.77M+1,651.39%+$62.08M0.14
Fuller & Thaler Asset Management, Inc.$63.08M0.912.66M+1.65%+$1.02M0.28
Los Angeles Capital Management LLC$58.24M0.842.45M+948.27%+$52.68M0.19
Jacobs Levy Equity Management$57.09M0.832.41M+1.74%+$973,784.280.21
Jupiter Fund Management$53.82M0.782.27M+148.17%+$32.13M0.15
Meditor Group Ltd$52.18M0.762.2M-16.66%-$10.43M76.68
Fidelity Investments$46.57M0.671.96M-36.12%-$26.33M<0.01
CalPERS$45.94M0.671.94M-1.95%-$912,869.370.03
Bellevue Group$45.16M0.651.9M-9.72%-$4.86M0.69
Northern Trust$45.06M0.651.9M-14.42%-$7.59M0.01
Ameriprise Financial$44.91M0.651.89M+1.81%+$798,445.420.01
Assenagon Asset Management S.A.$41.92M0.611.77M-9.38%-$4.34M0.1
Two Sigma Advisers LP$41.67M0.61.76M-4.6%-$2.01M0.07
Krensavage Asset Management LLC$37.16M0.541.57M-17.53%-$7.9M18.76
Russell Investments Group Ltd$36.42M0.531.53M+1.38%+$496,089.460.05
Brandywine Global Investment Management$36.09M0.521.52M+6.05%+$2.06M0.26
Psquared Asset Management AG$34.84M0.51.47M+5.55%+$1.83M10.51
Invesco$31.67M0.461.33M-24.55%-$10.3M0.01
Allspring Global Investments$30.35M0.441.28M-7.33%-$2.4M0.05
Acadian Asset Management$28.9M0.421.22M-31.24%-$13.13M0.1
Systematic Financial Management LLC$26.84M0.391.13M-0.36%-$96,106.550.76
Caligan Partners LP$26.12M0.381.1M+20.86%+$4.51M6.9
Bank of America$24.39M0.351.03M-35.42%-$13.38M<0.01
Woodline Partners LP$23.42M0.34987,0940%+$00.2
Goldman Sachs$21.51M0.31906,284-13.59%-$3.38M<0.01
RhumbLine Advisers$21.11M0.31889,688-5.83%-$1.31M0.02
Franklin Templeton Investments$20.46M0.3862,224+98.45%+$10.15M0.01
Blair William Co Il$18.01M0.26758,969+1.19%+$212,454.800.06
Candriam S C A$17.93M0.26755,477+6.16%+$1.04M0.12
Two Sigma$17.59M0.25741,123+28.86%+$3.94M0.03
Legal & General$16.02M0.23675,052-7.64%-$1.32M<0.01
Man Group Plc$15.63M0.23658,859-13.46%-$2.43M0.04
Ubs Asset Management Americas Inc$14.68M0.21618,552-0.32%-$46,819.290.01
EULAV Asset Management$14.48M0.21610,000-6.15%-$949,200.000.4
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.